Citigroup Raises DexCom (NASDAQ:DXCM) Price Target to $91.00

DexCom (NASDAQ:DXCM) had its price target boosted by Citigroup from $85.00 to $91.00 in a research note released on Wednesday morning,Benzinga reports. Citigroup currently has a buy rating on the medical device company’s stock.

DXCM has been the topic of several other research reports. Canaccord Genuity Group raised their price target on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company boosted their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday. Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Finally, Raymond James decreased their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

DexCom Price Performance

DXCM opened at $77.19 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company’s 50-day moving average price is $73.58 and its 200 day moving average price is $84.99. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market cap of $30.15 billion, a price-to-earnings ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the second quarter valued at $25,000. Sachetta LLC boosted its stake in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares in the last quarter. DT Investment Partners LLC grew its holdings in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the last quarter. Riverview Trust Co raised its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. Finally, ORG Partners LLC lifted its holdings in shares of DexCom by 1,992.0% during the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock valued at $59,000 after purchasing an additional 498 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.